---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-094967"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T18:51:31.950628+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jade Biosciences reports $336M cash; JADE101 Phase 1 data expected Q2 2026

## Summary
- Cash, equivalents, and investments of $336.2M as of Dec 31, 2025; runway into first half 2028.
- Q4 2025 net loss $31.9M vs $30.1M Q4 2024; full year net loss $127.4M.
- JADE101 Phase 1 interim data expected Q2 2026; Phase 2 IgA nephropathy trial to start mid-2026.
- JADE201 (anti-BAFF-R) Phase 1 in rheumatoid arthritis expected Q2 2026; interim data 2027.
- Raised ~$180M in Q4 2025 private placements from new and existing investors.

## SEC filing metadata
- accession: 0001193125-26-094967
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000119312526094967/0001193125-26-094967-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000119312526094967/d69373d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-094967
- JSON: https://secwatch.observer/filing/0001193125-26-094967.json
- Plain text: https://secwatch.observer/filing/0001193125-26-094967.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.